β-Glucans (Saccharomyces cereviseae) Reduce Glucose Levels and Attenuate Alveolar Bone Loss in Diabetic Rats with Periodontal Disease.
The objective of this study was to assess the effects of oral ingestion of β-glucans isolated from Saccharomyces cereviseae on the metabolic profile, expression of gingival inflammatory markers and amount of alveolar bone loss in diabetic rats with periodontal disease. Diabetes mellitus was induced in 48 Wistar rats by intraperitoneal injection of streptozotocin (80 mg/kg). After confirming the diabetes diagnosis, the animals were treated with β-glucans (by gavage) for 28 days. On the 14th day of this period, periodontal disease was induced using a ligature protocol. β-glucans reduced the amount of alveolar bone loss in animals with periodontal disease in both the diabetic and non-diabetic groups (p < 0.05). β-glucans reduced blood glucose, cholesterol and triacylglycerol levels in diabetic animals, both with and without periodontal disease (p < 0.05). Furthermore, treatment with β-glucans reduced the expression of cyclooxygenase-2 and receptor activator of nuclear factor kappa-B ligand and increased osteoprotegerin expression in animals with diabetes and periodontal disease (p < 0.05). It was concluded that treatment with β-glucans has beneficial metabolic and periodontal effects in diabetic rats with periodontal disease.
Department of Veterinary Medicine, Physiology and Pharmacology Area, Federal University of Lavras, Lavras, Minas Gerais, Brazil.
Viviam de Oliveira
Vde O
Silva
Department of Veterinary Medicine, Physiology and Pharmacology Area, Federal University of Lavras, Lavras, Minas Gerais, Brazil.
Raquel Vieira
RV
Lobato
Department of Veterinary Medicine, Physiology and Pharmacology Area, Federal University of Lavras, Lavras, Minas Gerais, Brazil.
Eric Francelino
EF
Andrade
Laboratory of Orofacial Pain, Department of Physiological Sciences, Piracicaba Dental School, University of Campinas, Piracicaba, São Paulo, Brazil.
Cristina Gomes
CG
de Macedo
Laboratory of Orofacial Pain, Department of Physiological Sciences, Piracicaba Dental School, University of Campinas, Piracicaba, São Paulo, Brazil.
Juliana Trindade Clemente
JT
Napimoga
Laboratory of Immunology and Molecular Biology, São Leopoldo Mandic Institute and Research Center, Campinas, São Paulo, Brazil.
Marcelo Henrique
MH
Napimoga
Department of Surgery and Bucco-Maxillofacial Traumatology, Division of Periodontics, School of Dentistry of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
Michel Reis
MR
Messora
University of Southern California, Herman Ostrow School of Dentistry, Division of Periodontology Diagnostic Sciences, Dental Hygiene & Biomedical Science, Los Angeles, California, United States of America.
Ramiro Mendonça
RM
Murata
Department of Health Sciences, Physiology and Pharmacology Area, Federal University of Lavras, Lavras, Minas Gerais, Brazil.
Luciano José
LJ
Pereira
D016301:Alveolar Bone Loss / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D000818:Animals; D001786:Blood Glucose / Q000187:drug effects*; D002784:Cholesterol / Q000097:blood; D051546:Cyclooxygenase 2 / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D004195:Disease Models, Animal; D005881:Gingiva / Q000378:metabolism; D008297:Male; D053244:Osteoprotegerin / Q000378:metabolism; D010510:Periodontal Diseases / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D053245:RANK Ligand / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D012441:Saccharomyces cerevisiae / Q000378:metabolism*; D013311:Streptozocin / Q000494:pharmacology; D014280:Triglycerides / Q000097:blood; D047071:beta-Glucans / Q000494:pharmacology*
D001786:Blood Glucose; D053244:Osteoprotegerin; D053245:RANK Ligand; D014280:Triglycerides; D047071:beta-Glucans; D013311:Streptozocin; D002784:Cholesterol; D051546:Cyclooxygenase 2